[Tyr0] Gastric Inhibitory Peptide (23-42), human structure
|
Common Name | [Tyr0] Gastric Inhibitory Peptide (23-42), human | ||
|---|---|---|---|---|
| CAS Number | 121765-67-1 | Molecular Weight | 2584.93 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C119H182N34O31 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of [Tyr0] Gastric Inhibitory Peptide (23-42), human[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research[1][2]. |
| Name | [Tyr0] Gastric Inhibitory Peptide (23-42), human |
|---|
| Description | [Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | GIPR-/- mice have higher blood glucose levels and impaired initial insulin response after oral glucose loading. In GIPR+/+ mice, a high-fat diet did not increase postprandial intake blood glucose levels, whereas it significantly increased in GIPR-/- mice[2]. |
| Molecular Formula | C119H182N34O31 |
|---|---|
| Molecular Weight | 2584.93 |